Literature DB >> 6830458

Creatine kinase BB isoenzyme in CSF in neurologic diseases. Measurement by radioimmunoassay.

F E Pfeiffer, H A Homburger, T Yanagihara.   

Abstract

The concentration of creatine kinase BB isoenzyme (CK BB) was measured by radioimmunoassay in CSF from 306 patients with various neurologic disorders. Levels above 2.0 ng/mL were not found in patients without neurologic disease. Whereas mean CSF CK BB level was less than 2.0 ng/mL in groups of patients with systemic malignant neoplasms, latent syphilis, peripheral neuropathy, disk disease, polyradiculopathy, myelopathy, multiple sclerosis, neurodegenerative disease, encephalopathy, and hydrocephalus, it was elevated in groups of patients with convulsive disorder, CNS neoplasm, cerebrovascular disease, vasculitis, and meningoencephalitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6830458     DOI: 10.1001/archneur.1983.04050030063012

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  5 in total

1.  Serum creatine kinase isoenzyme levels in patients with cerebral tumours.

Authors:  A S David
Journal:  J Clin Pathol       Date:  1984-11       Impact factor: 3.411

2.  Immunoelectron microscopic investigation of creatine kinase BB-isoenzyme after cerebral ischemia in gerbils.

Authors:  H Tomimoto; K Yamamoto; H A Homburger; T Yanagihara
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

3.  Creatine kinase BB activity in serum of patients with acute stroke: correlation with the severity of brain damage.

Authors:  G Capocchi; C Tassi; S Ricci; M Zampolini; R Fausti; A Rossi
Journal:  Ital J Neurol Sci       Date:  1987-12

4.  Biochemical changes in the injured brain.

Authors:  Seelora Sahu; Deb Sanjay Nag; Amlan Swain; Devi Prasad Samaddar
Journal:  World J Biol Chem       Date:  2017-02-26

5.  Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and creatine kinase activity and isoenzymes in human brain tumours.

Authors:  N Durany; J Joseph; F F Cruz-Sánchez; J Carreras
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.